Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
173
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy

Meghna Yalamanchia Chicago Medical School, Rosalind Franklin University, Chicago, IL, USA
,
Akanksha Sharmab Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
,
Minh Nguyenb Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
,
Judy Truongb Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
,
Jose A. Carrillob Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
,
Naveed Wagleb Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
,
Jaya M. Gillb Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USA
&
Santosh Kesarib Department of Translational Neurosciences, Saint John Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3772-6000
ORCID Icon show all
Pages 2044-2046 | Received 23 Nov 2020, Accepted 31 Jan 2021, Published online: 21 Feb 2021

References

  • Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–424.
  • Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–1047.
  • Shenkier TN, Blay J-Y, O’Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group breast cancer radiotherapy patterns of practice in europe view project primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–2239.
  • Menon MP, Nicolae A, Meeker H, et al. Primary CNS T-cell lymphomas. Am J Surg Pathol. 2015;39(12):1719–1729.
  • Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859–863.
  • Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
  • Adachi JI, Mishima K, Wakiya K, et al. O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol. 2012;107(1):147–153.
  • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
  • Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001;53(3):259–265.
  • Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–3068.
  • Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004;40(11):1682–1688.
  • Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010;97(3):389–392.
  • Querfeld C, Rosen ST, Guitart J, et al. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res. 2011;17(17):5748–5754.
  • Bird TG, Whittaker S, Wain EM, et al. Temozolomide for central nervous system involvement in mycosis fungoides. Int J Dermatol. 2016;55(7):751–756.
  • Zheng M, Perry AM, Bierman P, et al. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathology. 2017;37(6):509–516.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.